Emergent BioSolutions Inc. EBS 深 滬
已收盤 02-06 16:00:00 美东时间
10.92
+0.380
+3.61%
華盛通- 最 高10.96
- 今 開10.65
- 成交量 97.51万股
- 最 低 10.40
- 昨 收 10.54
- 總市值 5.74亿
- 52周最高 14.06
- 市盈率 靜 --
- 換手率 1.86%
- 52周最低 4.02
- 委 比 72.91%
- 總股本 5252.00万
- 歷史最高 137.61
- 量 比 1.44
- 振 幅 5.31%
- 歷史最低 1.42
- 每 手 1
- 風險率 2.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA Approves Emergent BioSolutions' sNDA For OTC NARCAN Nasal Spray To Be Packaged In New Carrying Case
Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid overdoses, and today, new solutions like the NARCAN® carrying case
01-14 21:05
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness
Emergent BioSolutions announced FDA approval of a new carrying case for OTC NARCAN® Nasal Spray, designed to be portable, discreet, and durable, containing two doses. Surveys show 74% of consumers prefer this discreet packaging, rising to 81% among college students. The goal is to encourage daily carry of naloxone for opioid emergencies. Only 10% of the population currently carries it, so this packaging aims to boost readiness and accessibility. ...
01-14 13:00
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Emergent BioSolutions Inc. announced that CEO Joe Papa will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The audio link and slides will be available on the company’s Investor section website for up to 30 days. Emergent BioSolutions focuses on protecting and saving lives by providing solutions for health threats like smallpox, mpox, and Ebola. For more information, visit their website or follow them on LinkedI...
01-07 12:59
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
Emergent BioSolutions announced that the U.S. FDA has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility to manufacture and test raxibacumab, a monoclonal antibody for treating and preventing inhalational anthrax. The approval supports the company's multi-year transformation strategy to streamline its manufacturing network. The Winnipeg facility, with over 45 years of experience, now adds production c...
2025-12-12 13:30
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
<p>Emergent BioSolutions celebrates the 10-year anniversary of the FDA approval of NARCAN® (naloxone HCl) Nasal Spray, the first FDA-approved nasal naloxone spray for opioid overdose treatment. Over 85 million doses have been distributed, saving countless lives. In 2023, NARCAN® became the first OTC naloxone product, increasing accessibility. Efforts include training first responders, expanding distribution, and advocating for legal protections. ...
2025-11-18 13:00
美股牛股 | CMBM涨超27%！与星链携手推出全新集成网络方案；医疗股GH绩后大涨近28%
CMBM涨超27%！与星链携手推出全新集成网络方案；Q3收入同比增长39%超预期，医疗股GH绩后大涨近28%；MTSR涨超22%，拟获诺和诺德要约收购>>
2025-10-31 14:55
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
A recent survey of U.S. policy opinion leaders highlights growing concerns over biological attacks, with 65% believing the likelihood of such an attack is rising, compared to 60% for nuclear threats. Nearly half (45%)认为美国对生物攻击准备不足。专家指出，生物攻击的相对低成本和易实施性使其比核武器更具威胁。此外，调查显示生物威胁被视为优先的国家安全问题，超过核威胁。超过70%的受访者认为生物攻击比核攻击更容易实施，接近一半认为生物攻击更可能发生。调查还强调了国际 treaties如CWC和BTWC的限制，以及非传统生物剂如芬太尼带来的持续挑战。
2025-10-28 12:00
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
Emergent BioSolutions renews commitment to combating opioid crisis through awareness, education, and increased access to naloxone products like NARCAN® and KLOXXADO®. The company highlights September observances such as National Preparedness Month, Recovery Month, and Opioid Awareness Day. Emergent partners with organizations like the National Safety Council and Penington Institute to promote workplace safety and community education. The company ...
2025-09-24 20:05
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
Emergent BioSolutions has secured a $29 million international government contract for medical countermeasures against threats like smallpox, anthrax, and botulism. This is the second procurement this year, with $26 million set to be received in 2025. The orders reflect increasing global defense preparedness and align with NATO's commitment to raising defense spending, supporting Emergent's international expansion and multi-year growth plan.
2025-09-19 12:34
